SynthesisMolecular biology reports2025
Analysis of PIK3CA mutation prevalence variation among colorectal cancer populations: a comprehensive review.
Synthesis in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Application of Systems Genetics to Investigate Molecular Pathology of Early-Onset Colorectal Cancer.Chemical biology & drug design · 2026Review
- Construction and Validation of Multi-Omics Predictive Models for Colorectal Cancer Using Machine-Learning Approaches.Pharmacogenomics and personalized medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most frequent cancer worldwide. It is the second leading cause of cancer-related death, affecting both men and women. It has been described that 20-25% of colorectal tumors have mutations in the PIK3CA gene, mainly in three hotspots: E542 and E545 and H1047. The aim of this study was to compare the prevalence of PIK3CA gene mutations in colorectal tumors based on a systematic review of a selection of studies. Nighty seven studies enrolling 48,446 patients were eligible for inclusion. Most studies were conducted in Asian (41.2%) and European countries (34.0%). The global prevalence ranged from 0 to 80%, with a mean prevalence of 13.7%. Fourteen studies reported a prevalence of less than 5%, 22 between 5 and 10%, 32 between 10 and 15% and 29 showed a prevalence of more than 15%. Mutations were more common in exon 9 than in exon 20 (9.5% vs. 4.7%). After discussing a number of possible reasons that could explain the differences in prevalence, it is very hard to deduce which is the main factor influencing the observed frequency.
Indexed as
Identifiers
41258360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.